Cervical cancer risk is high among immune suppressed women.
Dr Huftless and colleagues from Minnesota, USA evaluated inflammatory bowel disease (IBD) with medications and risk of cervical cancer.
The team compared women aged 15 to 69 years who had inflammatory bowel disease with age-matched women without inflammatory bowel disease between 1996 and 2006.
|The adjusted odds ratio of IBD with risk of cervical cancer was 1.5|
|Alimentary Pharmacology & Therapeutics|
Cervical cancer was ascertained using the Kaiser Permanente Northern California Cancer Registry.
Inflammatory bowel disease medications of interest were aminosalicylates, corticosteroids, immune modulators and infliximab.
Odds of cervical cancer were analyzed with adjusted logistic regression.
The prevalence of Pap smear testing was compared using a log binomial model.
The researchers found 10 cervical cancer cases occurred among 1165 women with inflammatory bowel disease, and 72 cancers among 12,124 controls.
The adjusted odds ratio of inflammatory bowel disease with risk of cervical cancer was 1.5.
The team found that the medication odds ratio were 1.7 for aminosalicylates, 2.8 for corticosteroids and 3.5 for immune modulators.
The research team observed that no cancer case used infliximab.
The adjusted absolute increase in Pap smears among inflammatory bowel disease women compared to women without inflammatory bowel disease was 4%.
Dr Huftless' team concluded, "Although a trend of elevated risk for cervical cancer with inflammatory bowel disease and inflammatory bowel disease medications was observed, it was not statistically significant."
"Regular cervical cancer screening for women with inflammatory bowel disease is recommended."